Opaleye Management Inc. 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Opaleye Management Inc. disclosed 58 US equity positions worth $1.1bn in its Q2 2026 13F filing. The largest position was LQDA at 17.7% of the reported book, followed by ETON and HROW. Against the Q1 2026 filing, it opened 8 new positions, added to 14 and reduced 10 among the top 50 holdings.
What did Opaleye Management Inc. own in Q2 2026? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | LQDA LIQUIDIA CORPORATION | Healthcare | 17.7% | $195.1m | 2,447,500 | -4% | reduced |
| 2 | ETON ETON PHARMACEUTICALS INC | 9.4% | $103.5m | 2,860,000 | 0% | held | |
| 3 | HROW HARROW INC | 9.2% | $101.9m | 2,400,000 | -15% | reduced | |
| 4 | IRON DISC MEDICINE INC | Healthcare | 5.7% | $62.5m | 855,000 | 103% | added |
| 5 | URGN UROGEN PHARMA LTD | Healthcare | 4.8% | $53.0m | 1,439,996 | 1% | added |
| 6 | APGE APOGEE THERAPEUTICS INC | Healthcare | 4.7% | $51.8m | 390,000 | 0% | held |
| 7 | MGTX MEIRAGTX HLDGS PLC | Healthcare | 4.3% | $48.0m | 3,550,000 | 67% | added |
| 8 | SOL-GEL TECHNOLOGIES LTD | 3.4% | $37.1m | 500,000 | 0% | held | |
| 9 | RZLT REZOLUTE INC | 3.0% | $32.8m | 6,300,000 | 0% | held | |
| 10 | TGTX TG THERAPEUTICS INC | Healthcare | 2.7% | $29.4m | 535,000 | 0% | held |
| 11 | IMMX IMMIX BIOPHARMA INC | 2.2% | $24.2m | 2,345,000 | – | new | |
| 12 | CBIO CRESCENT BIOPHARMA INC. | 2.2% | $23.7m | 1,319,351 | 1% | added | |
| 13 | STOK STOKE THERAPEUTICS INC | Healthcare | 2.1% | $22.9m | 700,000 | 0% | held |
| 14 | ALPHA COGNITION INC | 1.9% | $20.9m | 2,895,467 | 13% | added | |
| 15 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 1.8% | $20.3m | 500,000 | 0% | held |
| 16 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.7% | $18.7m | 100,000 | 0% | held |
| 17 | GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 1.6% | $18.0m | 745,000 | – | new |
| 18 | ALMS ALUMIS INC | Healthcare | 1.4% | $15.5m | 550,000 | 0% | held |
| 19 | CDXS CODEXIS INC | Healthcare | 1.4% | $15.3m | 6,785,000 | 0% | held |
| 20 | REPL REPLIMUNE GROUP INC | Healthcare | 1.4% | $15.3m | 1,384,993 | – | new |
| 21 | XOMA ROYALTY CORPORATION | 1.3% | $14.4m | 338,374 | 13% | added | |
| 22 | MBX MBX BIOSCIENCES INC | Healthcare | 1.3% | $14.4m | 260,000 | 0% | held |
| 23 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 1.2% | $13.6m | 122,500 | -0% | held |
| 24 | EDIT EDITAS MEDICINE INC | Healthcare | 1.1% | $12.5m | 3,861,930 | 100% | added |
| 25 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.1% | $12.3m | 100,000 | 0% | held |
| 26 | CABA CABALETTA BIO INC | Healthcare | 1.1% | $12.0m | 3,863,800 | 180% | added |
| 27 | QTTB Q32 BIO INC | 1.1% | $11.9m | 931,000 | -26% | reduced | |
| 28 | ANNX ANNEXON INC | Healthcare | 0.9% | $9.8m | 1,714,451 | -26% | reduced |
| 29 | VSTM VERASTEM INC | Healthcare | 0.6% | $6.9m | 1,800,000 | – | new |
| 30 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 0.6% | $6.9m | 1,412,656 | 0% | held |
| 31 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 0.6% | $6.5m | 935,000 | 0% | held |
| 32 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 0.5% | $5.9m | 600,000 | 0% | held |
| 33 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.5% | $5.8m | 310,000 | -10% | reduced |
| 34 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 0.5% | $5.3m | 700,000 | 1214% | added | |
| 35 | LYEL LYELL IMMUNOPHARMA INC | 0.4% | $4.8m | 344,025 | 335% | added | |
| 36 | IRD OPUS GENETICS INC | 0.4% | $4.6m | 1,125,000 | 0% | held | |
| 37 | FDMT 4D MOLECULAR THERAPEUTICS IN | Healthcare | 0.4% | $4.4m | 334,437 | 198% | added |
| 38 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 0.4% | $4.2m | 250,000 | 2% | added |
| 39 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 0.4% | $4.1m | 1,185,000 | 3% | added |
| 40 | BDSX BIODESIX INC | 0.4% | $4.1m | 180,000 | -24% | reduced | |
| 41 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.3% | $3.4m | 1,000,000 | 5% | added |
| 42 | JBIO JADE BIOSCIENCES INC | Healthcare | 0.3% | $3.2m | 145,000 | -66% | reduced |
| 43 | SANUWAVE HEALTH INC | 0.3% | $3.1m | 306,140 | -69% | reduced | |
| 44 | FBIO FORTRESS BIOTECH INC | 0.2% | $2.7m | 890,000 | -15% | reduced | |
| 45 | DERM JOURNEY MED CORP | 0.2% | $2.5m | 350,000 | -64% | reduced | |
| 46 | PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 0.2% | $2.0m | 185,589 | – | new |
| 47 | INBX INHIBRX BIOSCIENCES INC | Healthcare | 0.2% | $1.9m | 20,291 | – | new |
| 48 | ENTA ENANTA PHARMACEUTICALS INC | Healthcare | 0.2% | $1.8m | 125,000 | 0% | held |
| 49 | HEMAB THERAPEUTICS HLDGS INC | 0.2% | $1.8m | 47,652 | – | new | |
| 50 | TRAX FIRST TRACKS BIOTHERAPEUTICS | 0.1% | $1.3m | 65,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.